SEHK

EC Healthcare Expects Third Quarter FY23 Sales Volume to Increase no less than 8% YoY

Retrieved on: 
Friday, January 20, 2023

The Board expects to record overall sales volume of no less than HK$1,000 million for the Quarter, representing a no less than 8% YoY increase.

Key Points: 
  • The Board expects to record overall sales volume of no less than HK$1,000 million for the Quarter, representing a no less than 8% YoY increase.
  • The Group expects to achieve a no less than 39% YoY increase for medical services sales volume.
  • In addition, the sales volume of other services declined by no less than 8% YoY.
  • The Group will also further enhance the resilience and ability to resist cyclical economic changes and further consolidate the healthcare market."

CITIC Telecom CPC Has a Rosy Start in 2023 with Multiple Distinguished Awards and Certifications

Retrieved on: 
Thursday, January 19, 2023

World-class innovation capabilities are recognized by PTC Awards, a CMMI Level 3 Certification and 3 awards in iFLYTEK AI Developer Competition

Key Points: 
  • World-class innovation capabilities are recognized by PTC Awards, a CMMI Level 3 Certification and 3 awards in iFLYTEK AI Developer Competition
    HONG KONG, Jan 19, 2023 - (ACN Newswire) - CITIC Telecom International CPC Limited (CITIC Telecom CPC), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited ("CITIC Telecom", SEHK: 1883), has been well recognized for its dedication to upholding the motto "Innovation Never Stops", in-depth industry know-how and continuous innovation.
  • At the start of the year, the company has won its first world-renowned honor at PTC Awards 2023 organized by Pacific Telecommunications Council (PTC).
  • Mr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC said, "We are very pleased that CITIC Telecom CPC has received multiple international awards and quality certifications for the continuous commitment and dedication of our team, which is also a testament to our innovative thinking and excellence in algorithms and computing.
  • Distinguished awards and certifications won by CITIC Telecom CPC include:
    -- Won at the iFLYTEK AI Developer Competition 2022 hosted by iFLYTEK Co., Ltd., China Information Industry Association (CIIA) and National Intelligent Voice Innovation Center.

Beauty Farm Medical and Health Industry Inc. Announces Proposed Listing on the Main Board of SEHK, Offer price at HK$19.32 per share

Retrieved on: 
Friday, December 30, 2022

The Company provides overall beauty and health management services through its well-established and widely recognized brand portfolio of BeautyFarm, Palaispa, CellCare and Neology.

Key Points: 
  • The Company provides overall beauty and health management services through its well-established and widely recognized brand portfolio of BeautyFarm, Palaispa, CellCare and Neology.
  • As of June 30, 2022, the overall service network of Beauty Farm comprised 352 stores, including 177 direct stores and 175 franchised stores.
  • Constant evolution of business model in response to market demand, offering clients overall beauty and health management services
    As the leading chain brand in China's beauty and health management service industry, Beauty Farm has provided traditional beauty services to clients for nearly three decades.
  • Beauty Farm Medical and Health Industry Inc.
    Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or "Company", stock code: 2373) is a leading player in China's beauty and health management service industry, which has large and loyal client base, extensive network with expansion efficiency, diversified services and product offerings as well as strong brand awareness.

CITIC Telecom CPC Clinches Two Innovation Awards at Asia Communication Awards 2022

Retrieved on: 
Monday, December 19, 2022

HONG KONG, Dec 19, 2022 - (ACN Newswire) - CITIC Telecom International CPC Limited (CITIC Telecom CPC), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited ("CITIC Telecom", SEHK: 1883) is honored to announce that it has received two major awards at the inaugural Asia Communication Awards 2022.

Key Points: 
  • HONG KONG, Dec 19, 2022 - (ACN Newswire) - CITIC Telecom International CPC Limited (CITIC Telecom CPC), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited ("CITIC Telecom", SEHK: 1883) is honored to announce that it has received two major awards at the inaugural Asia Communication Awards 2022.
  • Mr. Taylor Lam, Chief Strategy Officer of CITIC Telecom CPC said, "It's truly an honor for CITIC Telecom CPC to receive Cyber Security Award and AI Innovation Award at Asia Communication Awards 2022.
  • CITIC Telecom CPC's breakthrough AI Visual Security Solution has won the Cyber Security Award at Asia Communication Awards 2022.
  • CITIC Telecom CPC received AI Innovation Award for its AI-enabled Cognitive Object Recognition (COR) solutions, which run its breakthrough algorithm and technique to improve object mapping.

Kingsoft Cloud Announces Results of Extraordinary General Meeting Following Proposed Dual Primary Listing on Hong Kong Stock Exchange and New Board Appointment

Retrieved on: 
Thursday, December 29, 2022

Earlier on December 23, 2022, the Company announced the proposed dual primary listing of its ordinary shares, par value US$0.001 per share by way of introduction on the Main Board of The Stock Exchange of Hong Kong Limited.

Key Points: 
  • Earlier on December 23, 2022, the Company announced the proposed dual primary listing of its ordinary shares, par value US$0.001 per share by way of introduction on the Main Board of The Stock Exchange of Hong Kong Limited.
  • He, in his new roles, will be a valuable asset for the Board and drive the Company’s long-term growth.
  • Statements that are not historical facts, including but not limited to statements about Kingsoft Cloud’s beliefs and expectations, are forward-looking statements.
  • Further information regarding these and other risks is included in Kingsoft Cloud’s filings with the SEC.

Futu Announces Proposed Dual Primary Listing on The Stock Exchange of Hong Kong Limited

Retrieved on: 
Thursday, December 22, 2022

HONG KONG, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced the proposed dual primary listing of its Class A ordinary shares, par value US$0.00001 per share (the “Shares”) by way of introduction on the Main Board of The Stock Exchange of Hong Kong Limited (the “SEHK”).

Key Points: 
  • HONG KONG, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced the proposed dual primary listing of its Class A ordinary shares, par value US$0.00001 per share (the “Shares”) by way of introduction on the Main Board of The Stock Exchange of Hong Kong Limited (the “SEHK”).
  • The Company has received a letter of in-principle approval of its listing application from the SEHK on December 21, 2022 (Hong Kong Time) for the dual primary listing of the Shares on the Main Board of the SEHK.
  • The listing document relating to the proposed dual primary listing of the Shares by way of introduction on the Main Board of the SEHK (the “Listing Document”) has been published on the website of the SEHK on December 22, 2022 (Hong Kong Time).
  • With respect to the proposed dual primary listing on the Main Board of the SEHK, Goldman Sachs (Asia) L.L.C.

Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

Retrieved on: 
Tuesday, January 3, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement.
  • Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally.
  • “We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China.
  • The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen.

Biocytogen and Hansoh Pharma Announce an Antibody License Agreement

Retrieved on: 
Tuesday, January 3, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice™ Platforms and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMice™ Platforms and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement.
  • Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally.
  • “We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China.
  • The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen.

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California.

Key Points: 
  • SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that Antengene will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th, 2023 at 9:30 a.m. PST in San Francisco, California.
  • The presentation will be made by Dr. Jay Mei, Antengene's Founder, Chairman and CEO.
  • Details of the event are as follow:
    An archived version of the presentation also will be available on the Company website following the live presentation.
  • You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect.

New Oriental to Report Second Quarter 2023 Financial Results on January 17, 2023

Retrieved on: 
Thursday, December 29, 2022

BEIJING, Dec. 29, 2022 /PRNewswire/ -- New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced that it will report its financial results for the second quarter ended November 30, 2022, before the U.S. market opens on January 17, 2023.

Key Points: 
  • BEIJING, Dec. 29, 2022 /PRNewswire/ -- New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU/ 9901.SEHK), a provider of private educational services in China, today announced that it will report its financial results for the second quarter ended November 30, 2022, before the U.S. market opens on January 17, 2023.
  • New Oriental's management will host an earnings conference call at 8 AM on January 17, 2023, U.S. Eastern Time (9 PM on January 17, 2023, Beijing/Hong Kong Time).
  • Participants can join the conference using the below options:
    Dialing-in to the conference call:
    Please register in advance of the conference, using the link provided below.
  • Upon registering, you will be provided with participant dial-in numbers, and unique personal PIN.